NRX Pharmaceuticals Inc.(NRXP),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community - To The Moon

At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.

Close

NRXP NRX Pharmaceuticals Inc.

Trading 05-18 10:42:51 EDT

3.03

-0.25

-7.62%

High3.42	Low2.90	Vol1.20M
Open3.39	D1 Closing3.28	Amplitude15.85%
Mkt Cap100.19M	Tradable Cap73.56M	Total Shares33.07M
T/O3.76M	T/O Rate4.95%	Tradable Shares24.28M
P/B--	ROE--	EPS0.00
52wk High--	52wk Low--	P/E--
Dividend--	Div.Yield--	ROA--

Loading ...

{"stockData":{"symbol":"NRXP","market":"US","secType":"STK","nameCN":"NRX Pharmaceuticals Inc.","latestPrice":3.03,"timestamp":1779115358076,"preClose":3.28,"halted":0,"volume":1202258,"delay":0,"changeRate":-0.07621951219512195,"floatShares":24277600,"shares":33067630,"eps":-1.339999,"marketStatus":"Trading","change":-0.25,"latestTime":"05-18 10:42:51 EDT","open":3.39,"high":3.4199,"low":2.9,"amount":3758879.8349344,"amplitude":0.158506,"askPrice":3.04,"askSize":120,"bidPrice":3.03,"bidSize":132,"shortable":0,"etf":0,"ttmEps":-1.339999,"tradingStatus":2,"nextMarketStatus":{"tag":"Post-Mkt","tradingStatus":3,"beginTime":1779134400000},"marketStatusCode":2,"adr":0,"exchange":"NASDAQ","adjPreClose":3.28,"preHourTrading":{"tag":"盘前","latestPrice":3.37,"preClose":3.28,"latestTime":"09:27 EDT","volume":112217,"amount":383291.43750239996,"timestamp":1779110870249,"change":0.09,"changeRate":0.027439,"amplitude":0.099817},"postHourTrading":{"tag":"盘后","latestPrice":3.2496,"preClose":3.28,"latestTime":"19:58 EDT","volume":51115,"amount":164800.5987,"timestamp":1778889536671,"change":-0.0304,"changeRate":-0.009268,"amplitude":0.045701},"volumeRatio":4.871384,"impliedVol":1.2569,"impliedVolPercentile":0.4622},"requestUrl":"/m/hq/s/NRXP/tweets","defaultTab":"tweets","newsList":[{"id":"2636655027","title":"NRX Pharmaceuticals (Nasdaq:Nrxp) Reports First Quarter 2026 Financial Results and Provides Corporate Update","url":"https://stock-news.laohu8.com/highlight/detail?id=2636655027","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2636655027?lang=en_us&edition=fundamental","pubTime":"2026-05-18 19:00","pubTimestamp":1779102000,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260518:nTUA6JVMPR:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["NRXP","BK4007"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2636935027","title":"Press Release: NRx Pharmaceuticals (Nasdaq:NRXP) Reports First Quarter 2026 Financial Results and Provides Corporate Update","url":"https://stock-news.laohu8.com/highlight/detail?id=2636935027","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2636935027?lang=en_us&edition=fundamental","pubTime":"2026-05-18 19:00","pubTimestamp":1779102000,"startTime":"0","endTime":"0","summary":"Key highlights from the first quarter of operations under the expanded management team include the following:. -- Anticipated FDA decision on the Company's ANDA for Preservative-Free. Ketamine in Q3 2026, with favorable preliminary determinations already. received from the FDA Office of Generic Drugs on bioequivalence, labeling,-- Initiation of commercial manufacturing of Ketamine at the 1 million dose. per month level with recent FDA inspection of the manufacturing facility. and granting of inspection status consistent with launch of an ANDA drug.-- Completed a Type C meeting with the FDA Division of Psychiatry Products. and CDER leadership, in which the Agency expressed openness to existing. clinical trial data and Real World Evidence supporting approval without. antibodies, cell lines, and Phase 2 data targeting HERVs implicated in. WILMINGTON, Del., May 18, 2026  -- NRx Pharmaceuticals, Inc.   a clinical-stage biopharmaceutical company, today announced financial results for the qua","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU1720051108.HKD","LU0006306889.USD","LU0390134368.USD","LU1989772840.SGD","IE00BZ1G4Q59.USD","LU0234570918.USD","LU2111349929.HKD","LU1244550577.SGD","LU0267386448.USD","LU1064131342.USD","LU1791710582.SGD","LU0971096721.USD","LU1989772923.USD","LU2023251221.USD","LU0557290698.USD","LU0528227936.USD","R","TM","LU1162221912.USD","LU1668664300.SGD","LU0882574139.USD","NQmain","BK4022","LU0106261372.USD","LU2271345857.HKD","LU0053666078.USD","03160","LU0158827781.USD","BK4516","IND","LABU","NRXP","LU0314104364.USD","BK4534","BK4099","BK4232","BK4585","LU0795875169.SGD","LU1732799900.SGD","BK4604","LU0320765646.SGD","BK4555","LU1548497426.USD","LU1988902786.USD","BK4504","LU1732800096.USD","LU0225283273.USD","LU0106831901.USD","LU1363072403.SGD","BK4581"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2635537270","title":"NRX Pharmaceuticals Inc reports results for the quarter ended March 31 - Earnings Summary","url":"https://stock-news.laohu8.com/highlight/detail?id=2635537270","media":"Reuters","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2635537270?lang=en_us&edition=fundamental","pubTime":"2026-05-16 06:08","pubTimestamp":1778882923,"startTime":"0","endTime":"0","summary":"NRX Pharmaceuticals Inc reports results for the quarter ended March 31 - Earnings SummaryNRX Pharmaceuticals Inc NRXP.OQ reported a quarterly adjusted loss of 4 cents per share for the quarter ended M","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260515:nL8N41S293:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4007","NRXP"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2635534650","title":"NRX Pharmaceuticals Q1 EPS $(0.04) Up From $(0.34) YoY, Sales $1.068M","url":"https://stock-news.laohu8.com/highlight/detail?id=2635534650","media":"Benzinga","labels":["dataReport","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2635534650?lang=en_us&edition=fundamental","pubTime":"2026-05-16 05:55","pubTimestamp":1778882120,"startTime":"0","endTime":"0","summary":"NRX Pharmaceuticals (NASDAQ:NRXP) reported quarterly losses of $(0.04) per share. This is a 88.24 percent increase over losses of $(0.34) per share from the same period last year.  The company reported $1.068 million in","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"11c8fbbf839f433c9d274cef5f173382","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.benzinga.com/news/earnings/26/05/52619820/nrx-pharmaceuticals-q1-eps-0-04-up-from-0-34-yoy-sales-1-068m","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"NRX Pharmaceuticals Q1 EPS $(0.04) Up From $(0.34) YoY, Sales $1.068M","news_tag":"dataReport,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["NRXP","BK4007"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2635307870","title":"NRx Pharma Q1 FY26 net loss narrows to $1.43 million; revenue turns to $1.07 million","url":"https://stock-news.laohu8.com/highlight/detail?id=2635307870","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2635307870?lang=en_us&edition=fundamental","pubTime":"2026-05-16 04:39","pubTimestamp":1778877587,"startTime":"0","endTime":"0","summary":"NRX Pharmaceuticals posted a net loss of $1.43 million for quarter ended March 31, 2026, narrowing from a net loss of $5.51 million a year earlier.Revenue totaled $1.07 million, compared with no revenue a year earlier, reflecting patient services from Dura following its September 2025 acquisition.Operating loss widened to $4.74 million as total operating expense climbed to $5.81 million, led by selling, general and administrative costs of $3.81 million.Cash fell to $6.71 million at quarter-end from $7.8 million at Dec. 31, 2025, while net cash used in operating activities increased to $4.3 million from $3.48 million.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. NRX Pharmaceuticals Inc. published the original content used to generate ","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260515:nNDL3l6mcD:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4007","NRXP"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2635689080","title":"NRX Pharmaceuticals Inc  expected to post earnings of 29 cents a share - Earnings Preview","url":"https://stock-news.laohu8.com/highlight/detail?id=2635689080","media":"Reuters","labels":["dataReport","preview"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2635689080?lang=en_us&edition=fundamental","pubTime":"2026-05-15 21:34","pubTimestamp":1778852062,"startTime":"0","endTime":"0","summary":"NRX Pharmaceuticals Inc  expected to post earnings of29cents a share - Earnings Preview NRX Pharmaceuticals Inc NRXP.OQ NRXP.O is expected to  show a rise in quarterly revenue when it reports  results","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260515:nL8N41S1GT:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"dataReport,preview","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["NRXP","BK4007"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2635083762","title":"NRx Pharmaceuticals Earnings Are Imminent; These Most Accurate Analysts Revise Forecasts Ahead Of Earnings Call","url":"https://stock-news.laohu8.com/highlight/detail?id=2635083762","media":"Benzinga","labels":["express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2635083762?lang=en_us&edition=fundamental","pubTime":"2026-05-15 18:32","pubTimestamp":1778841127,"startTime":"0","endTime":"0","summary":"NRx Pharma (NRXP) set to release Q1 earnings on May 18. Analysts expect $19.43 million in revenue, with a loss of 11 cents per share. FDA clearance received for clinical trial.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"11c8fbbf839f433c9d274cef5f173382","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.benzinga.com/analyst-stock-ratings/price-target/26/05/52590777/nrx-pharmaceuticals-earnings-are-imminent-these-most-accurate-analysts-revise-forecasts-ahead-of-earnings-call","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4007","NRXP"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2635719622","title":"NRx Pharmaceuticals to report Q1 2026 results, host conference call","url":"https://stock-news.laohu8.com/highlight/detail?id=2635719622","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2635719622?lang=en_us&edition=fundamental","pubTime":"2026-05-14 19:02","pubTimestamp":1778756535,"startTime":"0","endTime":"0","summary":"NRx Pharmaceuticals to report Q1 2026 results, host conference call                  NRX Pharmaceuticals to release Q1 2026 financial results before US market open on May 18, 2026, with materials post","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260514:nNDL1tR1N6:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["SG9999014039.USD","IE00BN0W2W23.USD","IE00BN0W2V16.EUR","LU2095319765.USD","IE00B64PRP62.GBP","LU2210149790.SGD","IE00BN0W2T93.GBP","LU2210150020.SGD","BK4585","IE00BKPKM429.USD","IE00B3QW5Z07.USD","SG9999014005.SGD","NDAQ","BK4007","BK4588","BK4112","LU0314104364.USD","IE00BGHQF748.EUR","SG9999014013.SGD","SG9999014021.USD","NRXP"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2635719581","title":"NRX Pharmaceuticals, Inc. (Nasdaq:Nrxp) to Report First Quarter 2026 Financial Results and Provide Corporate Update","url":"https://stock-news.laohu8.com/highlight/detail?id=2635719581","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2635719581?lang=en_us&edition=fundamental","pubTime":"2026-05-14 19:00","pubTimestamp":1778756404,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260514:nTUA5P361R:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4007","NRXP"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2634038285","title":"NRX Pharmaceuticals Inc  expected to post earnings of 29 cents a share - Earnings Preview","url":"https://stock-news.laohu8.com/highlight/detail?id=2634038285","media":"Reuters","labels":["dataReport","preview"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2634038285?lang=en_us&edition=fundamental","pubTime":"2026-05-11 19:46","pubTimestamp":1778499970,"startTime":"0","endTime":"0","summary":"NRX Pharmaceuticals Inc  expected to post earnings of29cents a share - Earnings Preview NRX Pharmaceuticals Inc NRXP.OQ NRXP.O is expected to  show a rise in quarterly revenue when it reports  results","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260511:nL8N41O12T:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"dataReport,preview","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["NRXP","BK4007"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2633014460","title":"NRx Pharmaceuticals wins FDA clearance to start NRX-101 depression, suicidality trial","url":"https://stock-news.laohu8.com/highlight/detail?id=2633014460","media":"Reuters","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2633014460?lang=en_us&edition=fundamental","pubTime":"2026-05-07 20:06","pubTimestamp":1778155588,"startTime":"0","endTime":"0","summary":"NRx Pharmaceuticals received FDA clearance to start MIND1, a placebo-controlled Phase 2/3 trial of NRX-101 as adjunct to active or sham robotic-assisted transcranial magnetic stimulation in adults with treatment-resistant major depressive disorder with suicidality.Trial planned to enroll 400 patients, including 240 in randomized portion across a US academic hospital and HOPE Therapeutics clinics, with additional enrollment at two US military treatment facilities.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260507:nNDLYhGyX:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4585","SG9999014039.USD","IE00BKPKM429.USD","LU2210149790.SGD","NDAQ","LU2210150020.SGD","LU0314104364.USD","IE00B64PRP62.GBP","SG9999014021.USD","IE00BN0W2T93.GBP","IE00B3QW5Z07.USD","NRXP","LU2095319765.USD","IE00BN0W2V16.EUR","BK4007","SG9999014005.SGD","BK4588","BK4112","IE00BGHQF748.EUR","SG9999014013.SGD","IE00BN0W2W23.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2633924438","title":"NRX Pharmaceuticals Is Maintained at Buy by D. Boral Capital","url":"https://stock-news.laohu8.com/highlight/detail?id=2633924438","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2633924438?lang=en_us&edition=fundamental","pubTime":"2026-05-06 04:45","pubTimestamp":1778013900,"startTime":"0","endTime":"0","summary":"Ratings actions from Benzinga: https://www.benzinga.com/quote/NRXP/analyst-ratings \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  May 05, 2026 16:45 ET (20:45 GMT)","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["NRXP","BK4007"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2633083914","title":"NRx Pharmaceuticals (Nasdaq:NRXP) Announces Initiation of Commercial Manufacturing for Preservative Free Ketamine","url":"https://stock-news.laohu8.com/highlight/detail?id=2633083914","media":"GlobeNewswire","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2633083914?lang=en_us&edition=fundamental","pubTime":"2026-05-05 19:00","pubTimestamp":1777978800,"startTime":"0","endTime":"0","summary":"Based on FDA Office of Generic Drugs guidance previously announced, NRx has transmitted an initial GMP manufacturing order to its US-based manufacturer.NRx has completed confirmatory GMP audits of man","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/05/05/3287507/0/en/NRx-Pharmaceuticals-Nasdaq-NRXP-Announces-Initiation-of-Commercial-Manufacturing-for-Preservative-Free-Ketamine.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4007","NRXP"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2630362206","title":"NRX Pharmaceuticals Is Maintained at Buy by Ascendiant Capital","url":"https://stock-news.laohu8.com/highlight/detail?id=2630362206","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2630362206?lang=en_us&edition=fundamental","pubTime":"2026-04-27 18:10","pubTimestamp":1777284600,"startTime":"0","endTime":"0","summary":"Ratings actions from Benzinga: https://www.benzinga.com/quote/NRXP/analyst-ratings \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  April 27, 2026 06:10 ET (10:10 GMT)","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["NRXP","BK4007"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2629839359","title":"NRX Pharmaceuticals Is Maintained at Buy by D. Boral Capital","url":"https://stock-news.laohu8.com/highlight/detail?id=2629839359","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2629839359?lang=en_us&edition=fundamental","pubTime":"2026-04-23 19:58","pubTimestamp":1776945480,"startTime":"0","endTime":"0","summary":"Ratings actions from Benzinga: https://www.benzinga.com/quote/NRXP/analyst-ratings \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  April 23, 2026 07:58 ET (11:58 GMT)","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4007","NRXP"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2629801046","title":"NRX Pharmaceuticals Inc - Receives Positive FDA Discipline Review Letter Requesting Only Minor Administrative Changes","url":"https://stock-news.laohu8.com/highlight/detail?id=2629801046","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2629801046?lang=en_us&edition=fundamental","pubTime":"2026-04-22 19:00","pubTimestamp":1776855600,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260422:nTUAWRN7R:4","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4007","NRXP"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2629801019","title":"NRX Pharmaceuticals Reports Positive FDA Office of Generic Drugs Feedback on Preservative-Free Ketamine Program","url":"https://stock-news.laohu8.com/highlight/detail?id=2629801019","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2629801019?lang=en_us&edition=fundamental","pubTime":"2026-04-22 19:00","pubTimestamp":1776855600,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260422:nTUAWRN7R:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["NRXP","BK4007"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2629101420","title":"NRX Pharmaceuticals Inc - FDA Office of Generic Drugs Voices Support for NRX Anda Approval in Current Review Cycle","url":"https://stock-news.laohu8.com/highlight/detail?id=2629101420","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2629101420?lang=en_us&edition=fundamental","pubTime":"2026-04-22 19:00","pubTimestamp":1776855600,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260422:nTUAWRN7R:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4007","NRXP"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2629010467","title":"NRX Pharmaceuticals Inc - in the Process of of Submitting Nda to Align Ketamine Labeling With Depression and Suicidality Treatment","url":"https://stock-news.laohu8.com/highlight/detail?id=2629010467","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2629010467?lang=en_us&edition=fundamental","pubTime":"2026-04-22 19:00","pubTimestamp":1776855600,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260422:nTUAWRN7R:3","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["NRXP","BK4007"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2628729056","title":"White House shift on psychedelics positive for NRx, says D. Boral","url":"https://stock-news.laohu8.com/highlight/detail?id=2628729056","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2628729056?lang=en_us&edition=fundamental","pubTime":"2026-04-20 22:07","pubTimestamp":1776694074,"startTime":"0","endTime":"0","summary":"D. Boral Capital analyst Jason Kolbert says NRx Pharmaceuticals (NRXP) is advancing a ketamine-based therapeutic strategy at a time when U.S. polic...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/white-house-shift-on-psychedelics-positive-for-nrx-says-d-boral-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/white-house-shift-on-psychedelics-positive-for-nrx-says-d-boral-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["NRXP","BK4007"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"websiteUrl":"http://www.salbergco.com","stockEarnings":[{"period":"1week","weight":0.0649},{"period":"1month","weight":0.3016},{"period":"3month","weight":0.8222},{"period":"6month","weight":0.3173},{"period":"1year","weight":0.3667},{"period":"ytd","weight":0.2103}],"compareEarnings":[{"period":"1week","weight":0.0021},{"period":"1month","weight":0.056},{"period":"3month","weight":0.0842},{"period":"6month","weight":0.1001},{"period":"1year","weight":0.2519},{"period":"ytd","weight":0.084}],"compareStock":{"symbol":"SPY","name":"SPDR S&P 500 ETF Trust"},"description":"NRx Pharmaceuticals, Inc., a clinical-stage bio-pharmaceutical company, develops novel therapeutics for the treatment of central nervous system disorders, including suicidal depression, post-traumatic stress disorder, and chronic pain. Its products include NRX-101 (D-cycloserine/Lurasidone), an oral, fixed dosed combination of D-cycloserine and lurasidone that earned food and drug administration-designated breakthrough therapy for suicidal treatment-resistant bipolar depression; and NRX-100 (ketamine), which has been awarded FDA fast track designation for the treatment of severe bipolar depression with acute suicidal ideation and behavior. The company has a partnership with Alvogen Inc. and Lotus Pharmaceutical Company; development and manufacturing agreement with Nephron Pharmaceuticals, Inc. and Alcami; license agreement with Apkarian Technologies; development and license agreement with Glytech; license agreement with Sarah Herzog Memorial Hospital. The company was founded in 2015 and is based in Wilmington, Delaware.","yearOnYearQuotes":[{"month":1,"riseRate":0.4,"avgChangeRate":-0.074525},{"month":2,"riseRate":0.2,"avgChangeRate":-0.102766},{"month":3,"riseRate":0.4,"avgChangeRate":-0.034339},{"month":4,"riseRate":0.4,"avgChangeRate":-0.100305},{"month":5,"riseRate":0.8,"avgChangeRate":0.077139},{"month":6,"riseRate":0.4,"avgChangeRate":-0.166652},{"month":7,"riseRate":0.4,"avgChangeRate":0.039708},{"month":8,"riseRate":0.2,"avgChangeRate":-0.14211},{"month":9,"riseRate":0.4,"avgChangeRate":-0.012776},{"month":10,"riseRate":0.6,"avgChangeRate":0.037482},{"month":11,"riseRate":0.4,"avgChangeRate":0.048439},{"month":12,"riseRate":0.6,"avgChangeRate":0.121824}],"exchange":"NASDAQ","name":"NRX Pharmaceuticals Inc.","nameEN":"NRX Pharmaceuticals Inc."},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.42.2","shortVersion":"4.42.2","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"NRX Pharmaceuticals Inc.(NRXP),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","description":"Find the latest NRX Pharmaceuticals Inc.(NRXP) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","keywords":"NRX Pharmaceuticals Inc.,NRXP,NRX Pharmaceuticals Inc.股票,NRX Pharmaceuticals Inc.股票老虎,NRX Pharmaceuticals Inc.股票老虎国际,NRX Pharmaceuticals Inc.行情,NRX Pharmaceuticals Inc.股票行情,NRX Pharmaceuticals Inc.股价,NRX Pharmaceuticals Inc.股市,NRX Pharmaceuticals Inc.股票价格,NRX Pharmaceuticals Inc.股票交易,NRX Pharmaceuticals Inc.股票购买,NRX Pharmaceuticals Inc.股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"NRX Pharmaceuticals Inc.(NRXP),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","og_description":"Find the latest NRX Pharmaceuticals Inc.(NRXP) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","og_image":"https://community-static.tradeup.com/news/9b6dafd60190235ae8e2c95f52c583a0"}}}